Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

NCT04263870 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma
Stomach Adenocarcinoma
Locally Advanced Unresectable Gastric Adenocarcinoma
Metastatic Gastric Cancer

Interventions

DRUG: sintilimab

Sponsor

Sichuan University